Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

22.61 -2.02 (-8.18%)
Delayed Quote Updated: 12:11 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden ↗
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Multiple Investor Conferences in November
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.